Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development , 1 Portland, Cambridge, Massachusetts 02139, United States.
Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development , 558 Eastern Point Rd, Groton, Connecticut 06340, United States.
ACS Chem Neurosci. 2017 Sep 20;8(9):1995-2004. doi: 10.1021/acschemneuro.7b00155. Epub 2017 Jun 30.
To enable the clinical development of our CNS casein kinase 1 delta/epsilon (CK1δ/ε) inhibitor project, we investigated the possibility of developing a CNS positron emission tomography (PET) radioligand. For this effort, we focused our design and synthesis efforts on the initial CK1δ/ε inhibitor HTS hits with the goal of identifying a compound that would fulfill a set of recommended PET ligand criteria. We identified [H]PF-5236216 (9) as a tool ligand that meets most of the key CNS PET attributes including high CNS MPO PET desirability score and kinase selectivity, CNS penetration, and low nonspecific binding. We further used [H]-9 to determine the binding affinity for PF-670462, a literature CK1δ/ε inhibitor tool compound. Lastly, [H]-9 was used to measure in vivo target occupancy (TO) of PF-670462 in mouse and correlated TO with CK1δ/ε in vivo pharmacology (circadian rhythm modulation).
为了推动我们中枢神经系统酪蛋白激酶 1 德尔塔/依克萨(CK1δ/ε)抑制剂项目的临床开发,我们研究了开发中枢神经系统正电子发射断层扫描(PET)放射性配体的可能性。为此,我们专注于最初的 CK1δ/ε 抑制剂高通量筛选(HTS)命中化合物的设计和合成,旨在确定一种能够满足一系列推荐的 PET 配体标准的化合物。我们发现 [H]PF-5236216(9)是一种工具配体,它符合大多数关键的中枢神经系统 PET 属性,包括高中枢神经系统单光子发射计算机断层扫描(SPECT)理想评分和激酶选择性、中枢神经系统穿透性以及低非特异性结合。我们进一步使用 [H]-9 来确定 PF-670462 的结合亲和力,PF-670462 是一种文献 CK1δ/ε 抑制剂工具化合物。最后,[H]-9 用于测量 PF-670462 在小鼠体内的靶标占有率(TO),并将 TO 与 CK1δ/ε 的体内药理学(昼夜节律调节)相关联。